Condition: Mucositis · Nephrotoxicity · Ototoxicity · Sponsor: Matrix Biomed, Inc.
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
This description comes directly from the study's public registry record.
Benji Crane · 6264376506 · bjcrane@matrixbiomed.com
Always discuss trial participation with your own doctor first.
| UCSD | La Jolla, California, United States | Recruiting |
| Mercy Medical Center | Merced, California, United States | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco, California, United States | Active Not Recruiting |
| Central Coast Medical Oncology | Santa Maria, California, United States | Recruiting |
| Mission Hope Health Center | Santa Maria, California, United States | Recruiting |
| Montefiore Medical Center-Einstein Campus | The Bronx, New York, United States | Recruiting |
| Wake Forest University Health Sciences | Winston-Salem, North Carolina, United States | Recruiting |
| Seattle Cancer Care Alliance | Seattle, Washington, United States | Recruiting |
| University of Washington Medical Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03480971